iA Global Asset Management Inc. Buys Shares of 7,174 Edwards Lifesciences Corporation $EW

iA Global Asset Management Inc. bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the first quarter, HoldingsChannel reports. The firm bought 7,174 shares of the medical research company’s stock, valued at approximately $574,000.

Several other institutional investors and hedge funds also recently modified their holdings of EW. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Edwards Lifesciences by 27.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock worth $9,356,000 after acquiring an additional 23,514 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Edwards Lifesciences by 39.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock valued at $194,907,000 after acquiring an additional 648,870 shares during the last quarter. Central Pacific Bank Trust Division purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $775,000. Stance Capital LLC increased its position in Edwards Lifesciences by 373.1% during the 3rd quarter. Stance Capital LLC now owns 45,994 shares of the medical research company’s stock worth $3,577,000 after purchasing an additional 36,272 shares in the last quarter. Finally, Sivik Global Healthcare LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $2,984,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of a number of recent research reports. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Wednesday, April 1st. Evercore reiterated an “outperform” rating and set a $93.00 price target on shares of Edwards Lifesciences in a report on Friday, April 24th. Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Barclays reissued an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.39.

Edwards Lifesciences Trading Up 2.5%

NYSE EW opened at $94.31 on Friday. The company has a market cap of $54.31 billion, a P/E ratio of 50.17, a P/E/G ratio of 2.31 and a beta of 0.86. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $94.47. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company has a 50-day moving average of $85.35 and a 200-day moving average of $83.49.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same period last year, the company earned $0.64 earnings per share. The company’s quarterly revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 58,977 shares of company stock worth $4,921,803 in the last 90 days. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.